Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also provides laboratory-testing services for Sjogren's syndrome, hearing loss, celiac disease, lupus, rheumatoid arthritis, systemic sclerosis, and other laboratory-testing services for autoimmune disorders. The company develops, manufactures, and sells products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. It serves public health authorities, non-governmental organisations, and clinical and reference laboratories through its direct sales force, as well as through a network of independent distributors and strategic partners. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-08-14 |
2024-06 |
-0.65 |
-0.55 |
0.1 |
15.38% |
2024-05-23 |
2024-03 |
0 |
-0.37 |
N/A |
N/A |
2024-04-04 |
2023-12 |
0 |
-0.68 |
N/A |
N/A |
2023-10-03 |
2023-06 |
0 |
-1 |
N/A |
N/A |
2023-07-06 |
2023-03 |
0 |
-0.8 |
N/A |
N/A |
2023-03-23 |
2022-12 |
-0.3 |
-0.9 |
-0.6 |
-200.00% |
Date |
Firm |
Action |
From |
To |
2016-10-04 |
Stephens & Co. |
Downgrade |
Overweight |
Equal-weight |
2015-05-28 |
Stephens & Co. |
Upgrade |
|
Overweight |
2014-04-29 |
Roth Capital |
Upgrade |
Neutral |
Buy |
2013-03-04 |
Craig-Hallum |
Upgrade |
|
Buy |
2013-01-21 |
Roth Capital |
Downgrade |
Buy |
Neutral |
2012-12-10 |
CJS Securities |
Upgrade |
|
Market Outperform |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Hunter Associates Investment Management LLC |
1.72M |
1.64M |
15.27% |
2023-06-29 |
Stonehill Capital Management LLC |
1.51M |
1.44M |
13.40% |
2023-06-29 |
Renaissance Technologies, LLC |
1.37M |
1.31M |
12.16% |
2023-06-29 |
Acadian Asset Management. LLC |
727.95K |
692.36K |
6.45% |
2023-06-29 |
Whitefort Capital Management, LP |
409.52K |
389.49K |
3.63% |
2023-06-29 |
Aristides Capital, LLC |
162.32K |
154.38K |
1.44% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-05-30 |
Fidelity NASDAQ Composite Index Fund |
5.17K |
4.80K |
0.05% |
Dividend |
Date |
0.22 |
2015-06-05 |
0.22 |
2014-06-06 |
0.2 |
2013-06-06 |
0.15 |
2012-06-06 |
0.1 |
2011-06-07 |
Split |
Date |
1 : 5 |
2024-02-23 |
1 : 5 |
2024-02-21 |
0.25 : 1 |
2005-06-02 |